文献速递胸部肿瘤消化系统肿瘤妇科肿瘤

癌症诊断分期对英格兰NHS医院诊疗费用的影响:基于个体患者数据的全国性回顾性队列研究

Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data.
PubMed 文献 · Lancet Oncol · 2026-02-16

该研究利用英格兰国家疾病登记服务2014至2017年确诊的50-79岁八类癌症患者个体数据,链接住院、门诊与急诊记录,以支付方视角估算按分期划分的净癌症相关医院费用。结直肠癌、头颈癌、淋巴瘤和卵巢癌费用随分期升高而增加,而肝癌胆管癌、肺癌、食管癌和胰腺癌在II期费用最高。作者认为这种异质性可支持更细致的早期检测经济学评价。

要点

  • 结直肠癌、头颈癌、淋巴瘤、卵巢癌的IV期平均费用分别为£37 838、£36 657、£42 667、£45 871。
  • 肝癌胆管癌、肺癌、食管癌、胰腺癌费用在II期最高(分别为£28 356、£29 553、£33 640、£39 351),I、III、IV期略低。
  • 费用在初始治疗期和临终期最高,多数癌种各期内月均费用随分期升高。

核心结论

  • 癌症相关NHS医院费用按诊断分期的模式因癌种而异,这种异质性可用于早期检测举措的细致经济学评价。

研究设计与样本

  • 研究为全国性回顾性、基于人群的队列研究,使用英格兰国家疾病登记服务收集的个体患者数据。
  • 链接国家医疗记录涵盖所有住院、门诊和急诊活动,以支付方视角计算费用;排除仅死亡证书登记、仅继发转移部位记录等情况。
  • 报告各癌种与分期的净癌症相关回归校正医院费用,包括总体、年度和按诊疗阶段划分的费用。

主要发现

  • 分析纳入333 657例癌症,其中女性147 334例(44·2%)、男性186 323例(55·8%)。
  • 结直肠癌、头颈癌、淋巴瘤和卵巢癌总体费用随分期升高,IV期平均费用分别为£37 838、£36 657、£42 667和£45 871。
  • 肝癌胆管癌、肺癌、食管癌和胰腺癌费用在II期最高,分别为£28 356、£29 553、£33 640和£39 351,I、III、IV期略低。
  • 费用在初始治疗期和临终期最高;多数癌种各期内月均费用随分期升高,但肝癌胆管癌、肺癌、食管癌和胰腺癌各期随访月数较少。

临床怎么用

  • 解读早期诊断干预的经济学价值时,应按癌种与分期分别估算费用,避免统一假设费用随分期单调上升。
  • 对肝癌胆管癌、肺癌、食管癌和胰腺癌,需注意II期费用最高及随访月数较少对费用比较的影响。

局限性

  • 研究为回顾性观察性设计,仅涵盖NHS医院诊疗费用,采用支付方视角。
  • 费用为回归校正后的净癌症相关费用,按分期比较可能受随访时长与诊疗阶段构成影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Estimates of the cost of cancer care are crucial for the economic evaluation of screening interventions and other early cancer diagnosis initiatives. However, data on the cost of cancer is scarce. This study estimated National Health Service (NHS) hospital care costs for eight cancer types by stage at diagnosis in England. METHODS: This national, retrospective, population-based cohort study used individual patient-level data collated by the National Disease Registration Service, NHS England. We included patients aged 50-79 years who were diagnosed with a colorectal, head and neck, liver and bile duct, lung, lymphoma, oesophageal, ovarian, or pancreatic cancer in England between Jan 1, 2014, and Dec 31, 2017. For each patient, we obtained linked national health-care records, incorporating all inpatient hospital care, outpatient activity, and accident and emergency department attendances, and costed these using a payer perspective. Patients were excluded if registration was death certificate only, records related only to a secondary metastatic site, sex and cancer type were incompatible, death status or date were uncertain, or there were zero health-care costs from 6 months before diagnosis to end of follow-up. Net, cancer-related, regression-adjusted hospital care costs were reported for each cancer type and stage overall, annually, and by phase of care. Within each annual period and phase, mean monthly costs were also estimated. FINDINGS: Of 359 106 cancer records registered, 345 629 cancers were available for analysis, and 333 657 cancers were included in the analysis (147 334 [44·2%] occurred in female patients and 186 323 [55·8%] in male patients; 303 227 [90·9%] among participants of White ethnicity, 4452 [1·3%] among participants of mixed or other ethnicity, 7870 [2·3%] among participants of Asian ethnicity, 4179 [1·3%] among participants of Black ethnicity, and 13 929 [4·2%] among participants of unknown ethnicity). Overall costs were higher at later stages for colorectal, head and neck, lymphoma, and ovarian cancers with mean stage IV costs of £37 838, £36 657, £42 667, and £45 871, respectively. Costs for liver and bile duct, lung, oesophageal, and pancreatic cancers were highest for those diagnosed at stage II (£28 356, £29 553, £33 640, and £39 351, respectively), and slightly lower at stages I, III, and IV. Health-care costs were highest in the initial treatment and the end-of-life phases of care. Within each phase, mean cost per month increased with stage for most cancer types studied, though fewer months of follow-up were observed in each phase for liver and bile duct, lung, oesophageal, and pancreatic cancers. INTERPRETATION: Cancer-related NHS hospital care costs by stage at diagnosis differed between cancer types; this heterogeneous pattern could inform detailed and nuanced economic evaluations of early detection initiatives. FUNDING: GRAIL Bio UK.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Pearson C, Jones DA, Baily G, et al. Influence of stage at cancer diagnosis on NHS hospital care costs in England: a national, retrospective, population-based cohort study using individual patient-level data. Lancet Oncol. 2026. PMID: 41713471. doi:10.1016/S1470-2045(25)00678-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。